IgM myeloma: A multicenter retrospective study of 134 patients

Jorge J. Castillo, Artur Jurczyszyn, Lucie Brozova, Edvan Crusoe, Jacek Czepiel, Julio Davila, Angela Dispenzieri, Marion Eveillard, Mark A. Fiala, Irene M. Ghobrial, Alessandro Gozzetti, Joshua N. Gustine, Roman Hajek, Vania Hungria, Jiri Jarkovsky, David Jayabalan, Jacob P. Laubach, Barbara Lewicka, Vladimir Maisnar, Elisabet E. ManasanchPhilippe Moreau, Elizabeth A. Morgan, Hareth Nahi, Ruben Niesvizky, Claudia Paba-Prada, Tomas Pika, Ludek Pour, John L. Reagan, Paul G. Richardson, Jatin Shah, Ivan Spicka, Ravi Vij, Anna Waszczuk-Gajda, Morie Gertz

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2,895 mg dL−1 with 19% of patients presenting with levels >6,000 mg dL−1. International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33%), 54 (44%), and 29 (24%) of patients, respectively. The malignant cells expressed CD20 (58%) and cyclin D1 (67%), and t(11;14) was the most common cytogenetic finding (39%). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival (P = 0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.

Original languageEnglish (US)
Pages (from-to)746-751
Number of pages6
JournalAmerican Journal of Hematology
Volume92
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Multicenter Studies
Immunoglobulin M
Retrospective Studies
Anemia
Kidney
Paraproteinemias
Survival
Cyclin D1
Hypercalcemia
Hematologic Neoplasms
Plasma Cells
Cytogenetics
Bone Marrow
Calcium
Serum

ASJC Scopus subject areas

  • Hematology

Cite this

Castillo, J. J., Jurczyszyn, A., Brozova, L., Crusoe, E., Czepiel, J., Davila, J., ... Gertz, M. (2017). IgM myeloma: A multicenter retrospective study of 134 patients. American Journal of Hematology, 92(8), 746-751. https://doi.org/10.1002/ajh.24753

IgM myeloma : A multicenter retrospective study of 134 patients. / Castillo, Jorge J.; Jurczyszyn, Artur; Brozova, Lucie; Crusoe, Edvan; Czepiel, Jacek; Davila, Julio; Dispenzieri, Angela; Eveillard, Marion; Fiala, Mark A.; Ghobrial, Irene M.; Gozzetti, Alessandro; Gustine, Joshua N.; Hajek, Roman; Hungria, Vania; Jarkovsky, Jiri; Jayabalan, David; Laubach, Jacob P.; Lewicka, Barbara; Maisnar, Vladimir; Manasanch, Elisabet E.; Moreau, Philippe; Morgan, Elizabeth A.; Nahi, Hareth; Niesvizky, Ruben; Paba-Prada, Claudia; Pika, Tomas; Pour, Ludek; Reagan, John L.; Richardson, Paul G.; Shah, Jatin; Spicka, Ivan; Vij, Ravi; Waszczuk-Gajda, Anna; Gertz, Morie.

In: American Journal of Hematology, Vol. 92, No. 8, 01.08.2017, p. 746-751.

Research output: Contribution to journalArticle

Castillo, JJ, Jurczyszyn, A, Brozova, L, Crusoe, E, Czepiel, J, Davila, J, Dispenzieri, A, Eveillard, M, Fiala, MA, Ghobrial, IM, Gozzetti, A, Gustine, JN, Hajek, R, Hungria, V, Jarkovsky, J, Jayabalan, D, Laubach, JP, Lewicka, B, Maisnar, V, Manasanch, EE, Moreau, P, Morgan, EA, Nahi, H, Niesvizky, R, Paba-Prada, C, Pika, T, Pour, L, Reagan, JL, Richardson, PG, Shah, J, Spicka, I, Vij, R, Waszczuk-Gajda, A & Gertz, M 2017, 'IgM myeloma: A multicenter retrospective study of 134 patients', American Journal of Hematology, vol. 92, no. 8, pp. 746-751. https://doi.org/10.1002/ajh.24753
Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J et al. IgM myeloma: A multicenter retrospective study of 134 patients. American Journal of Hematology. 2017 Aug 1;92(8):746-751. https://doi.org/10.1002/ajh.24753
Castillo, Jorge J. ; Jurczyszyn, Artur ; Brozova, Lucie ; Crusoe, Edvan ; Czepiel, Jacek ; Davila, Julio ; Dispenzieri, Angela ; Eveillard, Marion ; Fiala, Mark A. ; Ghobrial, Irene M. ; Gozzetti, Alessandro ; Gustine, Joshua N. ; Hajek, Roman ; Hungria, Vania ; Jarkovsky, Jiri ; Jayabalan, David ; Laubach, Jacob P. ; Lewicka, Barbara ; Maisnar, Vladimir ; Manasanch, Elisabet E. ; Moreau, Philippe ; Morgan, Elizabeth A. ; Nahi, Hareth ; Niesvizky, Ruben ; Paba-Prada, Claudia ; Pika, Tomas ; Pour, Ludek ; Reagan, John L. ; Richardson, Paul G. ; Shah, Jatin ; Spicka, Ivan ; Vij, Ravi ; Waszczuk-Gajda, Anna ; Gertz, Morie. / IgM myeloma : A multicenter retrospective study of 134 patients. In: American Journal of Hematology. 2017 ; Vol. 92, No. 8. pp. 746-751.
@article{5997726311b04721a9ce74a7559bbdb2,
title = "IgM myeloma: A multicenter retrospective study of 134 patients",
abstract = "IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10{\%} marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68{\%}). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70{\%}, respectively. The median serum IgM level was 2,895 mg dL−1 with 19{\%} of patients presenting with levels >6,000 mg dL−1. International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33{\%}), 54 (44{\%}), and 29 (24{\%}) of patients, respectively. The malignant cells expressed CD20 (58{\%}) and cyclin D1 (67{\%}), and t(11;14) was the most common cytogenetic finding (39{\%}). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival (P = 0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.",
author = "Castillo, {Jorge J.} and Artur Jurczyszyn and Lucie Brozova and Edvan Crusoe and Jacek Czepiel and Julio Davila and Angela Dispenzieri and Marion Eveillard and Fiala, {Mark A.} and Ghobrial, {Irene M.} and Alessandro Gozzetti and Gustine, {Joshua N.} and Roman Hajek and Vania Hungria and Jiri Jarkovsky and David Jayabalan and Laubach, {Jacob P.} and Barbara Lewicka and Vladimir Maisnar and Manasanch, {Elisabet E.} and Philippe Moreau and Morgan, {Elizabeth A.} and Hareth Nahi and Ruben Niesvizky and Claudia Paba-Prada and Tomas Pika and Ludek Pour and Reagan, {John L.} and Richardson, {Paul G.} and Jatin Shah and Ivan Spicka and Ravi Vij and Anna Waszczuk-Gajda and Morie Gertz",
year = "2017",
month = "8",
day = "1",
doi = "10.1002/ajh.24753",
language = "English (US)",
volume = "92",
pages = "746--751",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - IgM myeloma

T2 - A multicenter retrospective study of 134 patients

AU - Castillo, Jorge J.

AU - Jurczyszyn, Artur

AU - Brozova, Lucie

AU - Crusoe, Edvan

AU - Czepiel, Jacek

AU - Davila, Julio

AU - Dispenzieri, Angela

AU - Eveillard, Marion

AU - Fiala, Mark A.

AU - Ghobrial, Irene M.

AU - Gozzetti, Alessandro

AU - Gustine, Joshua N.

AU - Hajek, Roman

AU - Hungria, Vania

AU - Jarkovsky, Jiri

AU - Jayabalan, David

AU - Laubach, Jacob P.

AU - Lewicka, Barbara

AU - Maisnar, Vladimir

AU - Manasanch, Elisabet E.

AU - Moreau, Philippe

AU - Morgan, Elizabeth A.

AU - Nahi, Hareth

AU - Niesvizky, Ruben

AU - Paba-Prada, Claudia

AU - Pika, Tomas

AU - Pour, Ludek

AU - Reagan, John L.

AU - Richardson, Paul G.

AU - Shah, Jatin

AU - Spicka, Ivan

AU - Vij, Ravi

AU - Waszczuk-Gajda, Anna

AU - Gertz, Morie

PY - 2017/8/1

Y1 - 2017/8/1

N2 - IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2,895 mg dL−1 with 19% of patients presenting with levels >6,000 mg dL−1. International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33%), 54 (44%), and 29 (24%) of patients, respectively. The malignant cells expressed CD20 (58%) and cyclin D1 (67%), and t(11;14) was the most common cytogenetic finding (39%). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival (P = 0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.

AB - IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2,895 mg dL−1 with 19% of patients presenting with levels >6,000 mg dL−1. International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33%), 54 (44%), and 29 (24%) of patients, respectively. The malignant cells expressed CD20 (58%) and cyclin D1 (67%), and t(11;14) was the most common cytogenetic finding (39%). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival (P = 0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.

UR - http://www.scopus.com/inward/record.url?scp=85019759763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019759763&partnerID=8YFLogxK

U2 - 10.1002/ajh.24753

DO - 10.1002/ajh.24753

M3 - Article

C2 - 28383205

AN - SCOPUS:85019759763

VL - 92

SP - 746

EP - 751

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 8

ER -